Celldex Therapeutics, Inc. CLDX
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances
Chart by TradingView
1/9
Piotroski F — financial health
1.9
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.5M | -$258.8M | — | -$213.7M | $527.2M |
| 2024 | $7.0M | -$157.9M | — | -$159.7M | $747.0M |
| 2023 | $6.9M | -$141.4M | — | -$109.1M | $429.2M |
| 2022 | $2.4M | — | — | -$105.6M | $326.2M |
| 2021 | $4.7M | — | — | -$62.2M | $419.5M |
| 2020 | $7.4M | — | — | -$42.0M | $209.4M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.9 (grey)
- Working capital / assets 0.83
- Retained earnings / assets -3.112
- EBIT / assets -0.493
- Equity / liabilities 9.444
Source: SEC EDGAR filings · CIK 0000744218 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.